John McCamant joined the Medical Technology Stock Letter as associate editor in 1987 and was named editor of this leading investment newsletter in August 2000. He has spent 25 years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, Mr. McCamant uncovered investment opportunities and guided investment strategy. At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, and CBS Marketwatch.

Content from John McCamant

Pacira Targets Opiod Addiction
John McCamant Image John McCamant

It's "steady of she goes" at Pacira Pharmaceuticals (PCRX); overall the firm reported a steady quarter of pr…

Tickers: PCRX
Incyte: Bad News Buy?
John McCamant Image John McCamant

Incyte (INCY) and their partner Eli Lilly (LLY) have received a Complete Response Letter (CRL) from the FDA delaying the…

Tickers: INCY
Esperion: "Hitting on all Cylinders"
John McCamant Image John McCamant

Esperion Therapeutics (ESPR) and their experienced cardiovascular development team are hitting on all cylinders, obser…

Tickers: ESPR
Nektar: Breakthough in Pain Control
John McCamant Image John McCamant

Based upon positive results, Nektar Therapeutics (NKTR) expects to begin a licensing deal with a established leader in…

Tickers: NKTR
Esperion: "The New Kid in Town"
John McCamant Image John McCamant

Cardiovascular disease remains the world’s number one killer and one of the largest pharmaceutical markets, expla…

Tickers: ESPR | PFE
Incyte: Best in Class?
John McCamant Image John McCamant

Incyte (INCY) and their partner Lilly announced that the European Commission has granted marketing authorisation for O…

Tickers: INCY
Intrexon: Chimeras, CRSPR and Gene Therapy
John McCamant Image John McCamant

Intrexon (XON) has made a small yet strategic acquisition in buying GenVec (GNVC); with the purchase, XON gets AdenoVe…

Tickers: XON
Top Picks 2017: Madrigal
John McCamant Image John McCamant

Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John M…

Tickers: MDGL